COMMUNIQUÉS West-GlobeNewswire

SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
05/02/2024
SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report [...]
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
05/02/2024
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced [...]
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
05/02/2024
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/02/2024
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
05/02/2024
GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune [...]
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
05/02/2024
GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected in first half of 2024 NOVATO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- [...]
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
05/02/2024
EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to [...]
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
05/02/2024
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David [...]
IBA – Transparency Notification
05/02/2024
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 5, 2024 18:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
IBA - PUBLICATION RELATIVE À UNE NOTIFICATION DE TRANSPARENCE
05/02/2024
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 5 février 2024, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
Interim report for the first half of 2023/24 – Correction
05/02/2024
ANNOUNCEMENT NO. 250 5 February 2024 Interim report for the first half of 2023/24 – Correction In connection with the previously published interim report for the first half of 2023/24 (announcement no. 249), there were [...]
Immix Biopharma Announces Proposed Public Offering of Common Stock
05/02/2024
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it [...]
Interim report 2023/24 - Full-year guidance maintained despite continued challenging market conditions
05/02/2024
ANNOUNCEMENT NO. 249 5 February 2024 Interim report for the first half of 2023/24 Full-year guidance maintained despite continued challenging market conditions Rasmus Kofoed, CEO : “Rasmus Kofoed, CEO: “In the second [...]
Caira Surgical Featured on Bloomberg Intelligence’s Vanguards of Health Care Podcast
05/02/2024
Podcast Highlights Caira’s Radar-Based Surgical Tracking and Its Potential for Orthopedic Surgery NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Caira ® Surgical , an innovator in robotic and navigated orthopedic surgery, [...]
Court ruling in favor of Safe in its action against Neo Medical
05/02/2024
Court ruling in favor of Safe in its action against Neo Medical Eragny-sur-Oise – France – February 5, 2024, 6pm CET . Safe SA (the “Company” ) announces that on January 26, 2024, the Paris Judicial Court found in favor [...]
La justice tranche en faveur de Safe dans son procès contre Neo Medical
05/02/2024
La justice tranche en faveur de Safe dans son procès contre Neo Medical Eragny-sur-Oise - France - le 5 février 2024 à 18h . Safe SA (la « Société ») annonce que l’arrêt rendu par la Cour d’Appel de Paris le 26 janvier [...]
Protect Pharmaceutical Corp.'s President, Ali Yildiz, Issues a Letter to Shareholders
05/02/2024
ISTANBUL, Turkey, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) President, Ali Yildiz, publishes his February 2024 corporate update letter to Company Shareholders as follows: "February 5, [...]
Texas Infant to Become Fifth Child to Receive Life-Saving Gene Therapy Treatment on U.S. Soil
05/02/2024
DALLAS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Sufyan Pashai, a 4-month-old from Dallas, will travel to Minnesota and become the fifth child to receive life-saving gene therapy treatment on U.S. soil for metachromatic [...]
Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform
05/02/2024
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]

Pages